Scientific article

Essais thérapeutiques dans la dystrophie musculaire de Duchenne: entre espoirs et désespoirs

Published inRevue médicale suisse, vol. 8, no. 329, p. 409-412
Publication date2012

Duchenne muscular dystrophy is an X-linked progressive muscle disease. Since the discovery of the dystrophin gene responsible for the condition, various therapeutic strategies have been elaborated. In this paper we introduce three of them, which are well into clinical trials. The first is based on the ability to read through premature stop codons, the second is based on the technique of exon skipping. Both strategies are examples of "personalized medicines", tailored for specific mutation types. The third approach is a pharmacological one, potentially useful for all Duchenne patients, regardless of their mutation type. These first clinical trials raise many questions for researchers as well as for patients and their families, some of which are discussed.

  • Child
  • Genetic Therapy
  • Humans
  • Muscular Dystrophy, Duchenne/drug therapy/genetics
Citation (ISO format)
BLOETZER, Clemens, FLUSS, Joel Victor, JEANNET, Pierre-Yves. Essais thérapeutiques dans la dystrophie musculaire de Duchenne: entre espoirs et désespoirs. In: Revue médicale suisse, 2012, vol. 8, n° 329, p. 409–412.
Main files (1)
Article (Published version)
ISSN of the journal1660-9379

Technical informations

Creation10/08/2013 4:00:00 PM
First validation10/08/2013 4:00:00 PM
Update time03/14/2023 8:38:29 PM
Status update03/14/2023 8:38:29 PM
Last indexation01/16/2024 8:15:22 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack